Martin Fan
Stock Analyst at Wedbush
(4.80)
# 74
Out of 5,172 analysts
22
Total ratings
66.67%
Success rate
62.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Fan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ORKA Oruka Therapeutics | Reiterates: Outperform | $45 | $38.91 | +15.65% | 3 | Mar 13, 2026 | |
| ANAB AnaptysBio | Maintains: Outperform | $60 → $75 | $62.37 | +20.26% | 6 | Mar 12, 2026 | |
| RNAC Cartesian Therapeutics | Reiterates: Outperform | $38 | $6.51 | +483.72% | 2 | Mar 10, 2026 | |
| ZURA Zura Bio | Initiates: Outperform | $15 | $5.50 | +172.73% | 1 | Feb 9, 2026 | |
| ZBIO Zenas BioPharma | Reiterates: Outperform | $45 | $22.30 | +101.79% | 3 | Dec 22, 2025 | |
| VOR Vor Biopharma | Assumes: Neutral | $9 | $12.04 | -25.25% | 1 | Nov 25, 2025 | |
| IMA ImageneBio | Assumes: Underperform | $2 | $5.69 | -64.85% | 1 | Nov 25, 2025 | |
| SANA Sana Biotechnology | Maintains: Outperform | $5 → $6 | $3.11 | +92.93% | 2 | Nov 7, 2025 | |
| ARTV Artiva Biotherapeutics | Maintains: Outperform | $18 → $23 | $5.32 | +332.33% | 2 | Oct 17, 2025 | |
| ACRS Aclaris Therapeutics | Initiates: Outperform | $8 | $3.69 | +116.80% | 1 | May 28, 2025 |
Oruka Therapeutics
Mar 13, 2026
Reiterates: Outperform
Price Target: $45
Current: $38.91
Upside: +15.65%
AnaptysBio
Mar 12, 2026
Maintains: Outperform
Price Target: $60 → $75
Current: $62.37
Upside: +20.26%
Cartesian Therapeutics
Mar 10, 2026
Reiterates: Outperform
Price Target: $38
Current: $6.51
Upside: +483.72%
Zura Bio
Feb 9, 2026
Initiates: Outperform
Price Target: $15
Current: $5.50
Upside: +172.73%
Zenas BioPharma
Dec 22, 2025
Reiterates: Outperform
Price Target: $45
Current: $22.30
Upside: +101.79%
Vor Biopharma
Nov 25, 2025
Assumes: Neutral
Price Target: $9
Current: $12.04
Upside: -25.25%
ImageneBio
Nov 25, 2025
Assumes: Underperform
Price Target: $2
Current: $5.69
Upside: -64.85%
Sana Biotechnology
Nov 7, 2025
Maintains: Outperform
Price Target: $5 → $6
Current: $3.11
Upside: +92.93%
Artiva Biotherapeutics
Oct 17, 2025
Maintains: Outperform
Price Target: $18 → $23
Current: $5.32
Upside: +332.33%
Aclaris Therapeutics
May 28, 2025
Initiates: Outperform
Price Target: $8
Current: $3.69
Upside: +116.80%